Yang Xuesong, Zhang Qiang, Jiang Guo, Liu Junbo, Xie Chaofan, Cui Shu, Wu Tao
Department of Urology, Affiliated Hospital of North Sichuan Medical College, Nanchong, Sichuan, P. R. China.
Medicine (Baltimore). 2019 May;98(18):e15502. doi: 10.1097/MD.0000000000015502.
The aim of this meta-analysis was to understand the relationship between statin with benign prostatic hyperplasia (BPH) and lower urinary tract symptoms (LUTS).
A systematic literature search was conducted using PubMed, Embase, Cochrane Library, Chinese Medical and Biological Literature Database, China HowNet, Vip, and Wanfang. We calculated pooled odds ratios (OR) and 95% CI and standardized mean difference (SMD). Using Stata 12.0 and Review 5.3 for meta-analysis.
This meta-analysis included 11 articles and 49,128 participants. Results show statins could not reduce the incidence of BPH [OR = 0.77 (0.57, 1.03, P = .08]. For patients over 60 years old, statins could reduce the incidence of BPH [OR = 0.35 (0.22, 0.55), P < .0001]. Statins can slow down the progression of LUTS in BPH [SMD = -0.32 (-0.54, -0.10), P = .004], but there is no significant correlation between them in patients taking drugs for less than 1 year.
Statins have no significant effect on the incidence of BPH, but statins can reduce the risk of BPH for patients over 60 years old. For patients with hyperlipidemia, the duration of medication is more than 1 year, which can slow down the progression of LUTS. However, more high-quality and large sample size studies are needed to further improve and verify.
本荟萃分析的目的是了解他汀类药物与良性前列腺增生（BPH）及下尿路症状（LUTS）之间的关系。
使用PubMed、Embase、Cochrane图书馆、中国生物医学文献数据库、知网、维普和万方进行系统的文献检索。我们计算了合并比值比（OR）和95%置信区间（CI）以及标准化均数差（SMD）。使用Stata 12.0和Review 5.3进行荟萃分析。
本荟萃分析纳入了11篇文章和49128名参与者。结果显示他汀类药物不能降低BPH的发病率[OR = 0.77（0.57，1.03，P = 0.08）]。对于60岁以上的患者，他汀类药物可降低BPH的发病率[OR = 0.35（0.22，0.55），P < 0.0001]。他汀类药物可减缓BPH患者LUTS的进展[SMD = -0.32（-0.54，-0.10），P = 0.004]，但在服药少于1年的患者中它们之间无显著相关性。
他汀类药物对BPH的发病率无显著影响，但可降低60岁以上患者患BPH的风险。对于高脂血症患者，用药时间超过1年可减缓LUTS的进展。然而，需要更多高质量、大样本量的研究来进一步完善和验证。
